In terms of liver cancer treatment, PD-1 antibodies significantly improved the prognosis of patients with advanced liver cancer, achieving an objective response rate (ORR) of 17%–20% and a complete remission in some patients (5, 6). Here, PDCD1 is linked to liver cancer.